Patents by Inventor Peter G. Smith

Peter G. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210130909
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 6, 2021
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
  • Patent number: 10953013
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 23, 2021
    Assignees: Millennium Pharmaceuticals, Inc., The General Hospital Corporation
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Patent number: 10889866
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 12, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
  • Publication number: 20200361915
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 19, 2020
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Patent number: 10745387
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 18, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Publication number: 20190100513
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: November 17, 2016
    Publication date: April 4, 2019
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Publication number: 20180318312
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Application
    Filed: August 30, 2016
    Publication date: November 8, 2018
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
  • Patent number: 9827246
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 28, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • Patent number: 9789972
    Abstract: A system for fuel and thermal management of fuel delivered to an engine is disclosed. The system includes a supply of fuel in fluid communication with a fuel inlet of the engine, and an oxygen sensor for measuring dissolved oxygen content in the fuel is in fluid communication with the fuel. The fuel is heated by transferring heat from engine oil in a heat exchanger. The temperature of the fuel is controlled by controlling engine oil flow and airflow through another heat exchanger upstream of the fuel/oil heat exchanger on the oil circulation path with engine oil.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 17, 2017
    Assignee: HAMILTON SUNDSTRAND CORPORATION
    Inventors: Peter G. Smith, Craig R. Bolt, Jonathan K. Niemeyer, Thomas G. Tillman
  • Patent number: 9644134
    Abstract: A method for recovering oil from a subterranean, hydrocarbon-bearing formation includes at least one injection well and injecting a carrier fluid including a diverting agent into a high permeability pathway within the formation. An activating fluid is injected into the high permeability pathway within the formation, resulting in the precipitation or swelling of the diverting agent. The permeability of the high permeability pathway is decreased within the formation containing the diverting agent to a permeability less than the permeability of the adjacent areas of the formation. A mineralization fluid may be injected that is oversaturated or becomes oversaturated upon interacting with the acid gas that causes mineral precipitation to seal off high-permeability pathways.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: May 9, 2017
    Assignee: ExxonMobil Upstream Research Company
    Inventors: Gary F. Teletzke, Jasper L. Dickson, Preeti Kamakoti, Stuart R. Keller, William B. Maze, Peter G. Smith, Jr., Yitian Xiao
  • Publication number: 20170105995
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: June 3, 2016
    Publication date: April 20, 2017
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Publication number: 20170107579
    Abstract: The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Inventors: Benjamin Stone AMIDON, James E. BROWNELL, James M. GAVIN, Erik M. KOENIG, Michael D. SINTCHAK, Peter G. SMITH
  • Patent number: 9481669
    Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 1, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim
  • Patent number: 9335051
    Abstract: A vane assembly has an outer support ring, an inner support ring, an outer liner ring, an inner liner ring, and a circumferential array of vanes. Each vane has a shell extending from an inboard end to an outboard end and at least partially through an associated aperture in the inner liner ring and an associated aperture in the outer liner ring. There is at least one of: an outer compliant member compliantly radially positioning the vane; and an inner compliant member compliantly radially positioning the vane.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: May 10, 2016
    Assignee: United Technologies Corporation
    Inventors: David C. Jarmon, Peter G. Smith
  • Publication number: 20150375868
    Abstract: A system for fuel and thermal management of fuel delivered to an engine is disclosed. The system includes a supply of fuel in fluid communication with a fuel inlet of the engine, and an oxygen sensor for measuring dissolved oxygen content in the fuel is in fluid communication with the fuel. The fuel is heated by transferring heat from engine oil in a heat exchanger. The temperature of the fuel is controlled by controlling engine oil flow and airflow through another heat exchanger upstream of the fuel/oil heat exchanger on the oil circulation path with engine oil.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 31, 2015
    Inventors: Peter G. Smith, Craig R. Bolt, Jonathan K. Niemeyer, Thomas G. Tillman
  • Publication number: 20150366886
    Abstract: The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: December 24, 2015
    Inventor: Peter G. Smith
  • Publication number: 20150192298
    Abstract: A turbofan engine includes a fan driven by a low pressure turbine through a gear reduction. The gear reduction has a gear ratio of greater than or equal to about 2.4. The low pressure turbine has an expansion ratio greater than or equal to about 5. The fan has a bypass ratio greater than or equal to about 8. In other features, a turbofan engine includes a variable geometry fan exit guide vane (FEGV) system having a multiple of circumferentially spaced radially extending fan exit guide vanes. Rotation of the fan exit guide vanes between a nominal position and a rotated position selectively changes a fan bypass flow path to permit efficient operation at various flight conditions.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 9, 2015
    Inventors: Karl L. Hasel, Peter G. Smith, Stuart S. Ochs
  • Publication number: 20150132106
    Abstract: A turbofan engine includes a fan variable area nozzle axially movable relative to the fan nacelle to vary a fan nozzle exit area and adjust a pressure ratio of the fan bypass airflow during engine operation.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 14, 2015
    Inventors: Peter G. Smith, Stuart S. Ochs, Frederick M. Schwarz
  • Publication number: 20150119410
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 30, 2015
    Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Publication number: 20150105411
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 16, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith